• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Infect Dis . Pooled sputum to optimise the efficiency and utility of rapid, point-of-care molecular SARS-CoV-2 testing

tetano

Editor, Senior Moderator
BMC Infect Dis


. 2021 Jul 8;21(1):665.
doi: 10.1186/s12879-021-06316-z.
Pooled sputum to optimise the efficiency and utility of rapid, point-of-care molecular SARS-CoV-2 testing


Alison Burdett[SUP] #[/SUP][SUP] 1 [/SUP], Christofer Toumazou[SUP] #[/SUP][SUP] 2 3 [/SUP], Rashmita Sahoo[SUP] 2 [/SUP], Adam Mujan[SUP] 2 [/SUP], Tsz-Kin Hon[SUP] 2 [/SUP], Judith Bedzo-Nutakor[SUP] 2 [/SUP], Nicola Casali[SUP] 2 [/SUP], Maria Karvela[SUP] 2 [/SUP], Mohammadreza Sohbati[SUP] 2 [/SUP], Graham S Cooke[SUP] 4 5 [/SUP], Gary W Davies[SUP] #[/SUP][SUP] 6 [/SUP], Luke S P Moore[SUP] #[/SUP][SUP] 7 8 9 [/SUP]



Affiliations

Abstract

Background: As SARS-CoV-2 testing expands, particularly to widespread asymptomatic testing, high sensitivity point-of-care PCR platforms may optimise potential benefits from pooling multiple patients' samples.
Method: We tested patients and asymptomatic citizens for SARS-CoV-2, exploring the efficiency and utility of CovidNudge (i) for detection in individuals' sputum (compared to nasopharyngeal swabs), (ii) for detection in pooled sputum samples, and (iii) by modelling roll out scenarios for pooled sputum testing.
Results: Across 295 paired samples, we find no difference (p = 0.1236) in signal strength for sputum (mean amplified replicates (MAR) 25.2, standard deviation (SD) 14.2, range 0-60) compared to nasopharyngeal swabs (MAR 27.8, SD 12.4, range 6-56). At 10-sample pool size we find some drop in absolute strength of signal (individual sputum MAR 42.1, SD 11.8, range 13-60 vs. pooled sputum MAR 25.3, SD 14.6, range 1-54; p < 0.0001), but only marginal drop in sensitivity (51/53,96%). We determine a limit of detection of 250 copies/ml for an individual test, rising only four-fold to 1000copies/ml for a 10-sample pool. We find optimal pooled testing efficiency to be a 12-3-1-sample model, yet as prevalence increases, pool size should decrease; at 5% prevalence to maintain a 75% probability of negative first test, 5-sample pools are optimal.
Conclusion: We describe for the first time the use of sequentially dipped sputum samples for rapid pooled point of care SARS-CoV-2 PCR testing. The potential to screen asymptomatic cohorts rapidly, at the point-of-care, with PCR, offers the potential to quickly identify and isolate positive individuals within a population "bubble".

Keywords: COVID-19; Coronavirus; Molecular diagnostics; PCR.
 
Back
Top Bottom